SEARCH

SEARCH BY CITATION

References

  • Abshire, T. & Kenet, G. (2004) Recombinant factor VIIa: review of efficacy, dosing regimens, and safety in patients with congenital or acquired factor VIII or IX inhibitors. Journal of Thrombosis and Haemostasis, 2, 899909.
  • Acharya, S.S., Coughlin, A., DiMichele, D.M. and the North American Rare Bleeding Disorder Group (2004) Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. Journal of Thrombosis and Haemostasis, 2, 248256.
  • Aledort, L. (2004) Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. Journal of Thrombosis and Haemostasis, 2, 861862.
  • Algiman, M., Dietrich, G., Nydegger, U., Boieldieu, D., Sultan, Y. & Kazatchkine, M. (1992) Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proceedings of the National Academy of Sciences of the United States of America, 89, 37953799.
  • Ananyeva, N.M., Lacroix-Desmazes, S., Hauser, C.A.E., Shima, M., Ovanesov, M.V., Khrenov, A.V. & Saenko, E.L. (2004) Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagulation and Fibrinolysis, 15, 109124.
  • Astermark, J., Berntorp, E., White, G.C., Kroner, B.L. and the MIBS Study Group (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia, 7, 267272.
  • Barthels, M. (1999) Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VIII and IX inhibitors. Thrombosis Research, 95, S31S38.
  • Batlle, J., Loures, E., Vila, P., Hernandez, M.C., Mendez, J.A., Torea, J., Rendal, E., Couselo, M.J., Filguera, A. & Lopez Fernandez, M.F. (1997) Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction. Annals of Hematology, 75, 111115.
  • Bluestone, J.A. & Abbas, A.K. (2003) Natural versus adaptive regulatory T cells. Nature Reviews, 3, 253257.
  • Brackmann, H.H. & Gormsen, J. (1977) Massive factor VIII infusion in haemophiliacs with factor VIII inhibitor, high responder. Lancet, 2, 933.
  • Bretscher, P.A. (1999) A two-step, two-signal model for the primary activation of precursor helper T cells. Proceedings of the National Academy of Sciences of the United States of America, 96, 185190.
  • Ciavarella, N., Schiavoni, M., Valenzano, E., Mangini, F. & Inchingolo, F. (1996) Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis, 26(suppl. 1), 150154.
  • Coyle, A.J. & Gutierrez-Ramos, J.-C. (2001) The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nature Immunology, 2, 203209.
  • Dazzi, F., Tison, T., Vianello, F., Radossi, P., Zerbinati, P., Carraro, P., Poletti, A. & Girolami, A. (1996) High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. British Journal of Haematology, 93, 688693.
  • DiMichele, D.M. (2003) Immune tolerance therapy dose as an outcome predictor. Haemophilia, 9, 382386.
  • DiMichele, D.M. & Kroner, B.L. (2000) Higher immune tolerance success rate with monoclonal when compared to rFVIII: an analysis of the NAITR. Blood, 96, 266a.
  • DiMichele, D.M., Kroner, B. and the Factor VIII/IX Subcommittee of the International Society for Thrombosis and Haemostasis (2000) The maintenance of tolerance after successful ITI in hemophilia A and B. Haematologica, 85(suppl. 10), 4042.
  • DiMichele, D.M., Kroner, B.L. and the North American Immune Tolerance Study Group (2002) The North American immune tolerance registry. Practices, outcomes, outcome predictors. Thrombosis and Haemostasis, 87, 5257.
  • Ewenstein, B., Collins, P., Shapiro, A., Tarantino, M., Blanchette, V., Rogy, S., Retzios, A., Navale, L., Sensel, M. & Tonetta, T. (2003) Global evaluation of ADVATE rAFF-PFM, an advanced category antihemophilic factor prepared using a plasma/albumin free method. Blood, 102, 52a.
  • Food and Drug Administration (2004) Center for Biologics Evaluation and Research. Transcript on Workshop on Factor VIII inhibitors. Available at: http://www.fda.gov/cber/minutes/workshop-min.htm; accessed 22 September 2004.
  • Freedman, J., Rand, M.L., Russell, O., Davis, C., Cheatley, P.L., Blanchette, V. & Garvey, M.B. (2003) Immunoadsorbtion may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion, 43, 15081513.
  • Giles, A., Verbruggen, B., Rivard, G., Teitel, J. & Walker, I. (1998a) A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thrombosis and Haemostasis, 79, 872876.
  • Giles, A.R., Rivard, G.E., Teitel, J & Walker, I. (1998b) Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfusion Science, 19, 139148.
  • Gill, J.C. (1999) The role of genetics in inhibitor formation. Thrombosis and Haemostasis, 82, 500504.
  • Gilles, J.G., Arnout, J., Vermylen, J. & Saint-Remy, J.M. (1993) Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood, 82, 24522461.
  • Gilles, J.G., Desqueper, B., Lenk, H., Vermylen, J. & Saint-Remy, J.M. (1996) Neutralizing anti-idiotypic antibodies to factor VIII inhibitors after densensitization in patients with hemophilia A. Journal of Clinical Investigation, 97, 13821388.
  • Gilles, J.G., Grailly, S.C., De Maeyer, M., Jacquemin, M.G., Vanderelst, L.P. & Saint Remy, J.M. (2004) In vivo neutralization of a C2 domain-specific human anti-factor VIII inhibitor be an anti-idiotypic antibody. Blood, 103, 26172623.
  • Goodeve, A.C. & Peake, I.R. (2003) The molecular basis of hemophilia A: genotype–phenotype relationships and inhibitor development. Seminars in Thrombosis and Hemostasis, 29, 2330.
  • Gringeri, A., Mantovani, L., Salone, L. & Mannucci, P.M. (2003) Cost of care and quality of life in hemophilia complicated by inhibitors: the cocis study group. Blood, 102, 23582363.
  • Hausl, C., Ahmad, R.U., Schwarz, H.P., Muchitsch, E.M., Turecek, P.L., Dorner, F. & Reipert, B.M. (2004) Preventing re-stimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders? Blood, 4, 115122.
  • Hay, C.R.M. (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia, 4, 558563.
  • Haya, S., Lopez, M.F., Aznar, J.A. & Battle, J. (2001) Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia, 7, 154159.
  • Healey, J.F., Lubin, I.M., Saenko, E.L., Hoyer, L.W., Scandella, D. & Lolla, P. (1995) Residues 484–508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. Journal of Biological Chemistry, 270, 1450514509.
  • Hoots, W.K. & Lusher, J. (2004) High-titer inhibitor development in hemophilia A: lack of product specificity. Journal of Thrombosis and Haemostasis, 2, 358359.
  • Hvid, I. & Rodriguez-Merchant, E.C. (2002) Orthopaedic surgery in haemophilic patients with inhibitors: an overview. Haemophilia, 8, 288291.
  • Jacquemin, M., Vantomme, V., Buhot, C., Lavend'homme, R., Burny, W., Demotte, N., Chaux, P., Peerlinck, K., Vermylen, J., Maillere, B., van der Bruggen, P. & Saint-Remy, J.-M. (2003) CD4+ T cell clones specific for wild type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood, 101, 13511358.
  • Jansen, M., Schmaldienst, S., Banyai, S., Quehenberger, P., Derfler, K., Horl, W.H. & Knobl, P. (2001) Treatment of coagulation inhibitors with extracorporeal immunoadsorbtion (Ig-Therasorb). British Journal of Haematology, 112, 9197.
  • Josic, D., Buchacher, A., Kannicht, C., Lim, Y.-P., Loster, K., Pock, K., Robinson, S., Schwinn, H. & Stadler, M. (1999) Degradation products of factor VIII which can lead to increased immunogenicity. Vox Sanguinis, 77, 9099.
  • Kenet, G., Lubetsy, A., Luboshitz, J. & Martinowitz, U. (2003) A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSevenTM). Journal of Thrombosis and Haemostasis, 1, 450455.
  • Key, N.S. & Nelsestuen, G.L. (2004) Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Seminars in Hematology, 41, 5154.
  • Kreuz, W., Mentzer, D., Auerswald, G., Becker, S. & Joseph-Steiner, J. (1996) Successful immune tolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia, 2(suppl. 1), 19.
  • Lacroix-Desmazes, S., Bayry, J., Misra, N., Horn, M.P., Villard, S., Pashov, A., Stieltjes, N., D'Oiron, R., Saint-Remy, J.M., Hoebeke, J., Kazatchkine, M.D., Reinbolt, J., Mohanty, D. & Kaveri, S.V. (2002) The prevalence of proteolytic antibodies against factor VIII in hemophilia A. New England Journal of Medicine, 346, 702703.
  • Lawler, P., White, B., Pye, S., Hermans, C., Riddell, A., Costello, C., Brown, S. & Lee, C.A. (2002) Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia, 8, 145148.
  • Lenk, H. and the ITT Study Group (2000) The German Registry of immune tolerance treatment in hemophilia – 1999 update. Haematologica, 85, 4547.
  • Linde, R., Ettinghausen, C.E., Voight, B., Klingebiel, T. & Kreuz, W. (2001) First successful inhibitor elimination with a new protocol in a high responding hemophilia A patient after failure of various immune tolerance induction regimens. Blood, 98 (Suppl.), 534a.
  • Ling, M., Duncan, E.M., Rodgers, S.E., Street, A.M. & Lloyd, J.V. (2003) Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. Journal of Thrombosis and Haemostasis, 1, 25482553.
  • Lollar, P. (2004) Pathogenic antibodies to coagulation factors. Part One. Factor VIII and IX. Journal of Thrombosis and Haemostasis, 2, 10821095.
  • Lorenzo, J.I., Lopez, A., Altisent, C. & Anzar, J.A. (2001) Incidence of factor VIII inhibitors in severe hemophilia: the importance of age. British Journal of Haematology, 113, 600603.
  • Lusher, J. (2002) First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Seminars in Thrombosis and Haemostasis, 28, 273276.
  • Lusher, J. (2004) Is the incidence and prevalence of inhibitors greater with recombinant products? No. Journal of Thrombosis and Haemostasis, 2, 863865.
  • Margaritis, P., Arruda, V.R., Aljamali, M., Camire, R.M., Schlachterman, A. & High, K.A. (2004) Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated factor VII. Journal of Clinical Investigation, 113, 10251031.
  • Mariani, G. & Kroner, B. (1999) International Immune Tolerance Registry, 1997 update. Vox Sanguinis, 77, 2527.
  • Mariani, G., Siragusa, S. & Kroner, B.L. (2003) Immune tolerance induction in hemophilia A: a review. Seminars in Thrombosis and Haemostasis, 29, 6975.
  • Mathias, M., Khair, K., Hann, I. & Liesner, R. (2004) Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe hemophilia. British Journal of Haematology, 125, 366368.
  • Matzinger, P. (2002) The danger model: a renewed sense of self. Science, 296, 301305.
  • McMillan, C.W., Shapiro, S.S., Whitehurst, D., Hoyer, L.W., Rao, A.V. & Lazerson, J. (1988) The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood, 71, 344348.
  • Nakaya, S.M., Brower, C.L., Johnson, M.J. & Thompson, A.R. (2004) Hemophilic genotypes: risk of inhibitor development and response to immune tolerance induction. Haemophilia, 10 (Epub ahead of print).
  • Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C., Lauroua, P. and the members of the French FEIBA Study Group (1997) Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and FIX inhibitors. Thrombosis and Haemostasis, 77, 11131119.
  • Nelsestuen, G.L., Stone, M., Martinez, M.B., Harvey, S.B., Foster, D. & Kisiel, W. (2001) Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Journal of Biological Chemistry, 276, 3982539831.
  • Nilsson, I.M. & Hedner, U. (1976) Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scandinavian Journal of Haematology, 16, 369382.
  • Oldenburg, J. (2002) Report to the FVIII and FIX Scientific Subcommittee of the International Society of Thrombosis and Hemostasis. Available at: http://www.med.unc.edu/isth/; accessed 22 September 2004.
  • Oldenburg, J., Picard, J.K., Schwaab, R., Brackmann, H.H., Tuddenham, E.G.D. & Simpson, E. (1997) HLA genotype of patients with severe haemophilia due to intron 22 inversion with and without inhibitors of factor VIII. Thrombosis and Haemostasis, 77, 238242.
  • Oldenburg, J., Schroder, J., Hermann Brackmann, H., Muller-Reible, C., Schwaab, R. & Tuddenham, E. (2004) Environmental and genetic factors influencing inhibitor development. Seminars in Hematology, 41, 8288.
  • Peerlinck, K., Arnout, J., Gilles, J.G., Saint-Remy, J.M. & Vermylen, J. (1993) A higher than expected incidence of factor VIII inhibitors in multi-transfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thrombosis and Haemostasis, 69, 115118.
  • Peerlinck, K., Arnout, J., Di Giambattista, M., Gilles, J.G., Laub, R., Jacquemin, M., Saint-Remy, J.M. & Vermylen, J. (1997) Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated factor VIII concentrate. Thrombosis and Haemostasis, 77, 8086.
  • Peerlinck, K., Jacquemin, M.G., Arnout, J., Hoylaerts, M.F., Gilles, J.G., Lavend'homme, R., Johnson, K.M., Freson, K., Scandella, D., Saint-Remy, J.-M. & Vermylen, J. (1999) Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia. Blood, 7, 22672273.
  • Ponder, K.P. (2003) Should gene therapy be used for newborns with hemophilia? Molecular Therapy, 7, 78.
  • Poon, M.C., Lillicrap, D., Hensman, C., Card, R. & Scully, M.F. (2002) Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thrombosis and Haemostasis, 87, 431435.
  • Prescott, R., Nakai, H., Saenko, E.L., Scharrer, I., Nilsson, I.M., Humphries, J.E., Hurst, D., Bray, G., Scandella, D. and the Recombinate and Kogenate Study Groups (1997) The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood, 89, 36633671.
  • Qian, J., Burkly, L.C., Smith, E.P., Ferrant, J.L., Hoyer, L.W., Scott, D.W. & Haudenschild, C.C. (2000a) Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. European Journal of Immunology, 9, 25482554.
  • Qian, J., Collins, M., Sharpe, A.H. & Hoyer, L.W. (2000b) Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood, 95, 13241329.
  • Ragni, M.V., Trucco, M., Jaworski, K., Yan, J., Feng, J., Hashimi, H., Hill, K.A., Sommer, S.S. and the Hemophilia Inhibitor Study (2003) Large deletion mutations are linked with hemophilia inhibitors of high titer and short tolerance induction. Blood, 102, 561a.
  • Reding, M.T., Wu, H., Krampf, M., Okita, D.K., Diethelm-Okita, B.M., Christie, B.A., Key, N.S. & Conti-Fine, B.M. (2000) Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thrombosis and Haemostasis, 84, 643652.
  • Reding, M.T., Wu, H., Krampf, M., Okita, D.K., Diethelm-Okita, B.M., Key, N.S. & Conti-Fine, B.M. (2001) CD4+ T cells specific for factor VIII as a target for specific suppression of inhibitor production. Advances in Experimental Medicine and Biology, 489, 119134.
  • Reding, M.T., Lei, S., Lei, H., Green, D., Gill, J. & Conti-Fine, B.M. (2002) Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thrombosis and Haemostasis, 88, 568575.
  • Rosendaal, F.R., Nieuwenhuis, H.K., van den Berg, H.M., Heijboer, H., Mauser-Bunschoten, E.P., van der Meer, J., Smit, C., Strengers, P.F.W., Briet, E. and the Dutch Hemophilia Study Group (1993) A sudden increase in factor VIII inhibitor development in multi-transfused hemophilia A patients in the Netherlands. Blood, 81, 21802186.
  • Roussel-Robert, V., Torchet, M.F., Legrand, F., Rothschild, C. & Stieltjes, N. (2003) Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia previously treated patients. Journal of Thrombosis and Haemostasis, 1, 24502451.
  • Salomon, O., Zivelin, A., Livnat, T., Dardik, R., Loewenthal, R., Avishai, O., Steinberg, D.M., Rosove, M.H., O'Connell, N., Lee, C.A. & Seligsohn, U. (2003) Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood, 101, 47834788.
  • Sawamoto, Y., Prescott, R., Zhang, D., Saenko, E.L., Mauser-Bunschoten, E., Peerlinck, K., van den Berg, M. & Scandella, D. (1998) Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thrombosis and Haemostasis, 79, 6268.
  • Scandella, D., Mattingly, M., de Graaf, S. & Fulcher, C.A. (1989) Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood, 74, 16181626.
  • Scharrer, I. & Ehrlich, H.J. (2004) Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges? Haemophilia, 10, 197198.
  • Sharathkumar, A., Lillicrap, D., Blanchette, V.S., Kern, M., Leggo, J., Stain, A.M., Brooker, L. & Carcao, M.D. (2003) Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. Journal of Thrombosis and Haemostasis, 1, 12281236.
  • Stasi, R., Brunetti, M., Stipa, E. & Amadori, S. (2004) Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood, 2, 44244428.
  • Thompson, A.R., Murphy, M.E.P., Liu, M.L., Saenko, E.L., Healey, J.F., Lollar, P. & Scandella, D. (1997) Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood, 5, 19021910.
  • Tjonnfjord, G.E., Brinch, L., Gedde-Dahl, T., III & Brosstad, F.R. (2004) activated prothrombin complex concentrate (feibaTM) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia, 10, 174179.
  • Tout, H., Obert, B., Houllier, A., Fressinaud, E., Rothschild, C., Meyer, D. & Girma, J.P. (2000) Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Thrombosis and Haemostasis, 83, 274281.
  • Tranholm, M., Kristensen, K., Kristensen, A.T., Pyke, C., Rojkaer, R. & Persson, E. (2003) Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood, 102, 36153620.
  • Turecek, P.L., Varadi, K. & Schwarz, H.P. (2004) Update on the mechanism of action of activated prothrombin complex concentrates. Current Hematology Reports, 3, 331337.
  • UK Haemophilia Centre Doctors’ Organization (UKHCDO) (2004) The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–1999. Journal of Thrombosis and Haemostasis, 2, 10471054.
  • Van der Bom, J.G., Mauser-Bunschoten, E.P., Fischer, K. & van den Berg, H.M. (2003) Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thrombosis and Haemostasis, 89, 475479.
  • Van Parijs, L. & Abbas, A.K. (1998) Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science, 280, 243248.
  • Verbruggen, B., Novakova, I., Wessels, H., Boezman, J., van den Berg, M. & Mauser-Bunschoten, E. (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability. Thrombosis and Haemostasis, 73, 247250.
  • Verbruggen, B., Giles, A., Samis, J., Verbeek, K., Mensink, E. & Novakova, I. (2001) The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thrombosis and Haemostasis, 86, 14351439.
  • Verbruggen, B., Van Heerde, W.L., Lourenssen, G., Mensink, E. & Novakova, I.R.O. (2003) The Nijmegen low-titer factor VIII inhibitor assay: a highly sensitive assay for the detection of low-titer factor VIII inhibitors (abstract). Thrombosis and Haemostasis (Suppl. 1), P1594.
  • Villard, S., Lacroix-Desmazes, S., Kieber-Emmons, T., Piquer, D., Grailly, S., Benhida, A., Kaveri, S.V., Saint-Remy, J.M. & Granier, C. (2003) Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-factor VIII inhibitor. Blood, 102, 949952.
  • Walker, I., Pai, M., Akabutu, J., Ritchie, B., Growe, G., Poon, M.C., Card, R., Ali, K., Israels, S. & Teitel, J. (1995) The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion, 3597, 548551.
  • Warrier, I. (2003) Data presented at the meeting of the Factor VIII and Factor IX Scientific Subcommittee of the SSC of the ISTH. 49th Annual Scientific and Standardization Committee meeting, Birmingham, UK, July 2003. Available at: http://www.med.unc.edu/isth/; accessed 22 September 2004.
  • White, II, G.C. (2003) Antenatal cell gene transfer: an immunological Trojan horse? Journal of Thrombosis and Haemostasis, 1, 1415.
  • White, G.C., II, McMillan, C.W., Blatt, P.M. & Roberts, H.R. (1982) Factor VIII inhibitors: a clinical overview. American Journal of Hematology, 13, 335342.
  • White, G.C., II, DiMichele, D.M., Mertens, K., Negrier, C., Peake, I.R., Prowse, C., Schwaab, R., Yoshioka, A. & Ingerslev, J. (1999) Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new Factor VIII and Factor IX concentrates. Recommendations of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis, 81, 462.
  • White, G.C., II, Rosendaal, F., Aledort, L.M., Lusher, J.M., Rothschild, C., Ingerslev, J. and Factor VIII and Factor IX Subcommittee (2001) Definitions in hemophilia. Recommendations of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis, 85, 560.
  • Wight, J. & Paisley, S. (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia, 9, 418435.
  • Xu, L., Gao, C., Sands, M.S., Cai, S.-R., Nichols, T.C., Bellinger, D.A., Rayner, R.A., McCorquodale, S. & Ponder, K.P. (2003) Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood, 101, 39243932.